[{"Assets_0_Q3_USD":4999024000.0,"EarningsPerShareBasic_1_Q3_USD":1.06,"EarningsPerShareBasic_3_Q3_USD":4.26,"EarningsPerShareDiluted_1_Q3_USD":1.03,"EarningsPerShareDiluted_3_Q3_USD":4.17,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":488528000.0,"NetIncomeLoss_1_Q3_USD":63526000.0,"NetIncomeLoss_3_Q3_USD":255641000.0,"StockholdersEquity_0_Q3_USD":2469297000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":61436000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":61360000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":60108000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":60030000.0,"Ticker":"JAZZ","CIK":"1232524","name":"JAZZ PHARMACEUTICALS PLC","OfficialName":"Jazz Pharmaceuticals plc Common Stock (Ireland)","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"10281986580.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171107"}]